We previously reported that hematolymphopoietic disease was more severe either through increased Kras expression or in the KrascomQ61R/+ mutant background, suggesting that this tissue was particularly sensitive to the level of active Kras to induce tumorigenesis [10]. The gene discussed is KRAS; the disease is glycogen storage disease VI.